Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
NCT05190419 is registered in ClinicalTrials.gov with UNION therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
- Lead sponsor
- UNION therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 30, 2021
- Completion date
- December 20, 2022
- Enrollment
- 202 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.